James S. Floyd

James S. Floyd

Auto-generated profile, based on publicly available information

James S. Floyd

University of Washington

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2015 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
JFJames S. Floyd
James S. Floyd
MBMarc Blondon
Marc Blondon
KMKathryn P. Moore
Kathryn P. Moore
EBEdward J. Boyko
Edward J. Boyko
NSNicholas L. Smith
Nicholas L. Smith

18 April 2012 in JAMA
Verified
Journal Article
Open access
PDF file
SHSusan R. Heckbert
Susan R. Heckbert
JFJames S. Floyd
James S. Floyd
NWNoel S. Weiss
Noel S. Weiss
DCDavid S. Carrell
David S. Carrell
BPBruce M. Psaty
Bruce M. Psaty
To the Editor: Studies of rare adverse drug reactions (ADRs) are difficult because they require large numbers of exposed persons to identify an adequate number of cases. Spontaneous adverse events reports have been used to identify cases of rhabdomyolysis, a rare but serious complication of statin use.1 A complex algorithm based on administrative data also has been used to identify cases of rhabdomyolysis and myopathy among enrollees of several large health plans.2,3 We conducted this population-based epidemiological study to evaluate use of the diagnostic code for rhabdomyolysis introduced in 2006 as a method of estimating the incidence of statin-related rhabdomyolysis and myopathy.

14 March 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JFJ S Floyd
J S Floyd
RKR Kaspera
R Kaspera
KMK D Marciante
K D Marciante
NWN S Weiss
N S Weiss
SHS R Heckbert
S R Heckbert
BPB M Psaty
B M Psaty

4 November 2022 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
DCDavid S Carrell
David S Carrell
SGSusan Gruber
Susan Gruber
JFJames S Floyd
James S Floyd
MBMaralyssa A Bann
Maralyssa A Bann
KCKara L Cushing-Haugen
Kara L Cushing-Haugen
JNJennifer C Nelson
Jennifer C Nelson
We sought to determine whether machine learning and natural language processing (NLP) applied to electronic medical records could improve performance of automated health-care claims-based algorithms to identify anaphylaxis events using data on 516 patients with outpatient, emergency department, or inpatient anaphylaxis diagnosis codes during 2015–2019 in 2 integrated health-care institutions in the Northwest United States. We used one site’s manually reviewed gold-standard outcomes data for model development and the other’s for external validation based on cross-validated area under the receiver operating characteristic curve (AUC), positive predictive value (PPV), and sensitivity. In the development site 154 (64%) of 239 potential events met adjudication criteria for anaphylaxis compared with 180 (65%) of 277 in the validation site. Logistic regression models using only structured claims data achieved a cross-validated AUC of 0.58 (95% CI: 0.54, 0.63). Machine learning improved cross-validated AUC to 0.62 (0.58, 0.66); incorporating NLP-derived covariates further increased cross-validated AUCs to 0.70 (0.66, 0.75) in development and 0.67 (0.63, 0.71) in external validation data. A classification threshold with cross-validated PPV of 79% and cross-validated sensitivity of 66% in development data had cross-validated PPV of 78% and cross-validated sensitivity of 56% in external data. Machine learning and NLP-derived data improved identification of validated anaphylaxis events.

27 November 2017 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
ZMZachary A. Marcum
Zachary A. Marcum
CFChristopher W. Forsberg
Christopher W. Forsberg
KMKathryn P. Moore
Kathryn P. Moore
IBIan H. de Boer
Ian H. de Boer
NSNicholas L. Smith
Nicholas L. Smith
JFJames S. Floyd
James S. Floyd

2 February 2021 in Epidemiology
Verified
Journal Article
Closed access
MBMaralyssa A. Bann
Maralyssa A. Bann
DCDavid S. Carrell
David S. Carrell
SGSusan Gruber
Susan Gruber
MSMayura Shinde
Mayura Shinde
RBRobert Ball
Robert Ball
JFJames S. Floyd
James S. Floyd
Background: Anaphylaxis is a life-threatening allergic reaction that is difficult to identify accurately with administrative data. We conducted a population-based validation study to assess the accuracy of ICD-10 diagnosis codes for anaphylaxis in outpatient, emergency department, and inpatient settings. Methods: In an integrated healthcare system in Washington State, we obtained medical records from healthcare encounters with anaphylaxis diagnosis codes (potential events) from October 2015 to December 2018. To capture events missed by anaphylaxis diagnosis codes, we also obtained records on a sample of serious allergic and drug reactions. Two physicians determined whether potential events met established clinical criteria for anaphylaxis (validated events). Results: Out of 239 potential events with anaphylaxis diagnosis codes, the overall positive predictive value (PPV) for validated events was 64% (95% CI = 58 to 70). The PPV decreased with increasing age. Common precipitants for anaphylaxis were food (39%), medications (35%), and insect bite or sting (12%). The sensitivity of emergency department and inpatient anaphylaxis diagnosis codes for all validated events was 58% (95% CI = 51 to 65), but sensitivity increased to 95% (95% CI = 74 to 99) when outpatient diagnosis codes were included. Using information from all validated events and sampling weights, the incidence rate for anaphylaxis was 3.6 events per 10,000 person-years (95% CI = 3.1 to 4.0). Conclusions: In this population-based setting, ICD-10 diagnosis codes for anaphylaxis from emergency department and inpatient settings had moderate PPV and sensitivity for validated events. These findings have implications for epidemiologic studies that seek to estimate risks of anaphylaxis using electronic health data.